This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
AbbVie (ABBV) Stock Moves -0.29%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session.
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
by Zacks Equity Research
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
The Zacks Analyst Blog Highlights AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands
by Zacks Equity Research
AbbVie, Lockheed Martin, Dell and Hamilton Beach Brands are included in this Analyst Blog.
Top Analyst Reports for AbbVie, Lockheed Martin & Dell
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Lockheed Martin Corporation (LMT) and Dell Technologies Inc. (DELL), as well as a micro-cap stock Hamilton Beach Brands Holding Company (HBB).
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
by Zacks Equity Research
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
Why AbbVie (ABBV) Dipped More Than Broader Market Today
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $213.59, marking a -1.42% move from the previous day.
Zacks Market Edge Highlights: Berkshire Hathaway, Aon plc and AbbVie
by Zacks Equity Research
Berkshire Hathaway, Aon plc and AbbVie are part of the Zacks Market Edge article.
Pfizer Stock Up Almost 6% in 3 Months: Time to Buy, Sell or Hold?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform.
3 Stocks Breaking Out Right Now
by Tracey Ryniec
Think every stock is selling off right now on tariff fears? Zacks Stock Strategist, Tracey Ryniec, shares a group of stocks bucking the trend.
Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bayer Aktiengesellschaft (BAYRY) and AbbVie (ABBV) have performed compared to their sector so far this year.
3 Top Cancer Biotechs to Keep An Eye On in 2025
by Kinjel Shah
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More
by Kinjel Shah
Bayer announces fourth-quarter results. NVO cuts cost of Wegovy for the uninsured. ABBV enters obesity space with new deal.
Here's How to Play AbbVie Stock as it Enters the Obesity Space
by Kinjel Shah
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Buy Johnson & Johnson (JNJ) Stock for Higher Highs?
by Shaun Pruitt
Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $211.48, moving +1.17% from the previous trading session.
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
by Zacks Equity Research
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
Should Invesco Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
by Zacks Equity Research
The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
by Zacks Equity Research
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.